HIF activation causes synthetic lethality between the VHL tumor suppressor and the EZH1 histone methyltransferase-Reference-Cited by-同舟云学术

HIF activation causes synthetic lethality between the VHL tumor suppressor and the EZH1 histone methyltransferase

Published:2017-07-12 Issue:398 Volume:9 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Chakraborty Abhishek A.¹^ORCID,Nakamura Eijiro¹,Qi Jun¹^ORCID,Creech Amanda²^ORCID,Jaffe Jacob D.²^ORCID,Paulk Joshiawa¹,Novak Jesse S.¹³,Nagulapalli Kshithija⁴,McBrayer Samuel K.¹,Cowley Glenn S.²^ORCID,Pineda Javier¹,Song Jiaxi¹³,Wang Yaoyu E.⁴,Carr Steven A.²,Root David E.²,Signoretti Sabina¹³,Bradner James E.¹^ORCID,Kaelin William G.¹²⁵⁶^ORCID

Affiliation:

1. Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02215, USA.

2. Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA 02142, USA.

3. Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA.

4. Center for Cancer Computational Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.

5. Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA.

6. Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA.

Abstract

Dysregulated H3K27 demethylase activity in pVHL-deficient cells increases dependence on the EZH1 H3K27 methyltransferase.

Funder

National Institutes of Health

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference60 articles.

1. Characterization of the Human Prolyl 4-Hydroxylases That Modify the Hypoxia-inducible Factor

2. Studies on the activity of the hypoxia-inducible-factor hydroxylases using an oxygen consumption assay

3. W. G. Kaelin Molecular biology of kidney cancer in Kidney Cancer: Principles and Practice P. N. Lara E. Jonasch Eds. (Springer ed. 2 2005) pp. 31–57.

4. Development of synchronous VHL syndrome tumors reveals contingencies and constraints to tumor evolution

5. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Newly developed preclinical models reveal broad‐spectrum CDK inhibitors as potent drugs for CRPC exhibiting primary resistance to enzalutamide;Cancer Science;2023-11-03

2. TheSLC1A1/EAAT3 Dicarboxylic Amino Acid Transporter is an Epigenetically Dysregulated Nutrient Carrier that Sustains Oncogenic Metabolic Programs;2023-09-05

3. Inflammatory Networks in Renal Cell Carcinoma;Cancers;2023-04-09

4. Development of drugs targeting hypoxia‐inducible factor against tumor cells with VHL mutation: Story of 127 years;Cancer Science;2023-01-31

5. The role of histone methylation in renal cell cancer: an update;Molecular Biology Reports;2022-12-28